Swiss Company DKSH Takes Over Rights to Rocephin® from Roche
Published
The company DKSH has acquired the rights to the medicine Rocephin® from Roche. The rights apply in more than 80 markets worldwide. DKSH is a service provider headquartered in Zurich, and Roche is one of the largest pharmaceutical companies in Switzerland, based in Basel.
Rocephin® is an antibiotic that treats infections caused by bacteria. With the takeover, DKSH is expanding its portfolio of proprietary healthcare products, meaning medicines and products that the company markets under its own name. The active ingredient has been known for years in many countries and is used in hospitals and medical practices.
For DKSH, the purchase strengthens its business in the healthcare sector. The company operates primarily in Asia, where it sells products for customers from various industries. Through the new rights, DKSH can offer and distribute the product itself in numerous markets.
With the sale of these rights, Roche is giving up part of its offering in these countries. Further details on the purchase price and the exact timeline of the takeover were not mentioned in the available information. However, the news shows that Swiss companies remain active in the international healthcare market and are deliberately reorganising their business.
Sources: boerse.de
More Switzerland news
- Olympic Winter Games 2038 in Switzerland? Private deficit guarantee is meant to pave the way
- Database Records 1,900 Swiss Banks Since the 18th Century
- Christoph Dürr achieves best Swiss result
- Swiss TPH builds new apartments at Bachgraben
- Swiss Re is among the highest-dividend SMI stocks
- AfD and Switzerland: Connections Come Into Focus
- Swiss Stock Exchange: SMI Extends Gains
- Swiss Ski: Three Highlights for Fans Beyond the Race Course